Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up

[1] Mak KH(1997)Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries J Am Coll Cardiol 30 171-179

[2] Moliterno DJ(2008)Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies Lancet 371 1800-1809

[3] Granger CB(2010)The role of endoplasmic reticulum stress in the progression of atherosclerosis Circ Res 107 839-850

[4] Miller DP(2002)Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2570-2581

[5] White HD(2008)Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580-591

[6] Wilcox RG(2007)Biology of incretins: GLP-1 and GIP Gastroenterology 132 2131-2157

[7] Califf RM(2015)Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 373 232-242

[8] Topol EJ(2015)Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies Diabetes Metab J. 39 373-383

[9] Mazzone T(2012)Cardiovascular biology of the incretin system Endocr Rev 33 187-215

[10] Chait A(2009)Revised equations for estimated GFR from serum creatinine in Japan Am J Kidney Dis 53 982-992

[1] Mak KH(1997)Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries J Am Coll Cardiol 30 171-179

[2] Moliterno DJ(2008)Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies Lancet 371 1800-1809

[3] Granger CB(2010)The role of endoplasmic reticulum stress in the progression of atherosclerosis Circ Res 107 839-850

[4] Miller DP(2002)Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2570-2581

[5] White HD(2008)Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580-591

[6] Wilcox RG(2007)Biology of incretins: GLP-1 and GIP Gastroenterology 132 2131-2157

[7] Califf RM(2015)Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 373 232-242

[8] Topol EJ(2015)Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies Diabetes Metab J. 39 373-383

[9] Mazzone T(2012)Cardiovascular biology of the incretin system Endocr Rev 33 187-215

[10] Chait A(2009)Revised equations for estimated GFR from serum creatinine in Japan Am J Kidney Dis 53 982-992